<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NUCYNTA- tapentadol hydrochloride solution </strong><br>Janssen Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use NUCYNTA<span class="Sup">®</span> safely and effectively. See full prescribing information for NUCYNTA<span class="Sup">®</span>.<br><br>NUCYNTA<span class="Sup">®</span> (tapentadol) oral solution  C-II<br>Initial U.S. Approval: 2008</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">NUCYNTA<span class="Sup">®</span> is an opioid analgesic indicated for the management of moderate to severe <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> in adults.  (<a href="#section-1">1</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Individualize dosing according to the severity of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> being treated, the previous experience with similar drugs and the ability to monitor the patient. (<a href="#S2.1">2.1</a>)</li>
<li>Initiate NUCYNTA<span class="Sup">®</span> with or without food at a dose of 2.5 mL (50 mg), 3.75 mL (75 mg), or 5 mL (100 mg) every 4 to 6 hours depending upon <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity. On the first day of dosing, the second dose may be administered as soon as one hour after the first dose, if adequate <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief is not attained with the first dose. Subsequent dosing is 2.5 mL (50 mg), 3.75 mL (75 mg), or 5 mL (100 mg) every 4 to 6 hours and should be adjusted to maintain adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> with acceptable tolerability. Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not been studied and are, therefore, not recommended. (<a href="#S2.2">2.2</a>)</li>
<li>Instructions for Use (<a href="#S2.7">2.7</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Oral Solution: 20 mg/mL  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Significant <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (<a href="#S4">4</a>)</li>
<li>Acute or severe bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercarbia</span> (<a href="#S4">4</a>)</li>
<li>Known or suspected <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> (<a href="#S4">4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to tapentadol or to any other ingredients of the product (<a href="#S4">4</a>)</li>
<li>Concurrent use of monoamine oxidase (MAO) inhibitors or use within the last 14 days. (<a href="#S4">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Misuse, Abuse and Diversion: NUCYNTA<span class="Sup">®</span> is a Schedule II controlled substance with abuse liability similar to other opioids: monitor patients closely for signs of misuse, abuse and addiction. (<a href="#S5.1">5.1</a>)</li>
<li>Elderly, cachectic, and debilitated patients and patients with chronic pulmonary disease: Monitor closely because of increased risk of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. (<a href="#S5.5">5.5</a>)</li>
<li>Interaction with CNS depressants including other opioids, sedatives, alcohol, and illicit drugs: Consider dose reduction of one or both drugs because of additive effects. (<a href="#S5.7">5.7</a>)</li>
<li>Hypotensive effect: Monitor for signs of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. (<a href="#S5.8">5.8</a>)</li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span> or <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>: Monitor for sedation and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Avoid use of NUCYNTA<span class="Sup">®</span> in patients with impaired consciousness or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> susceptible to intracranial effects of CO<span class="Sub">2</span> retention. (<a href="#S5.9">5.9</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>: Use with caution in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. (<a href="#S5.10">5.10</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span>: Potentially life-threatening condition could result from concomitant serotonergic administration. (<a href="#S5.11">5.11</a>)</li>
<li>Withdrawal: Withdrawal symptoms may occur if NUCYNTA<span class="Sup">®</span> is discontinued abruptly. (<a href="#S5.13">5.13</a>)</li>
<li>Impaired mental/physical abilities: Caution must be used with potentially hazardous activities. (<a href="#S5.14">5.14</a>) </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common (≥10%) adverse reactions were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.  (<a href="#section-6">6</a>)</p>
<p class="Highlighta"><span class="Bold"><br>To report SUSPECTED ADVERSE REACTIONS, contact Janssen Pharmaceuticals, Inc. at 1-800-526-7736 (1-800-JANSSEN) or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span></span>  (<a href="#section-6">6</a>)</p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>CNS depressants: Increased risk of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, profound sedation, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. When combined therapy with CNS depressant is contemplated, the dose of one or both agents should be reduced. (<a href="#S7.3">7.3</a>)</li>
<li>Mixed agonist/antagonist opioids (i.e., pentazocine, nalbuphine, and butorphanol): May reduce <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> and/or precipitate withdrawal symptoms. (<a href="#S7.5">7.5</a>)</li>
<li>Monitor for signs of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> when NUCYNTA<span class="Sup">®</span> is used concurrently with SSRIs, SNRIs, tricyclic antidepressants, or triptans. (<a href="#S7.4">7.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Pregnancy: Based on animal data, may cause fetal harm. (<a href="#S8.1">8.1</a>)</li>
<li>Nursing mothers: Closely monitor infants of nursing women receiving. NUCYNTA<span class="Sup">®</span>. (<a href="#S8.3">8.3</a>)</li>
<li>Renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>: not recommended in patients with severe renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Reduce dose in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#S8.7">8.7</a>, <a href="#S8.8">8.8</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION, Medication Guide, and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 11/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Individualization of Dosage</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Initiation of Therapy</a></h2>
<h2><a href="#section-2.3" class="toc">2.3	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-2.5" class="toc">2.5	Elderly Patients</a></h2>
<h2><a href="#section-2.6" class="toc">2.6	Cessation of Therapy</a></h2>
<h2><a href="#section-2.7" class="toc">2.7	Instructions for Use</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Abuse Potential</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Life Threatening <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Accidental Exposure</a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Interactions with Alcohol, Other Opioids, and Drugs of Abuse</a></h2>
<h2><a href="#section-5.5" class="toc">5.5	Elderly, Cachectic, and Debilitated Patients</a></h2>
<h2><a href="#section-5.6" class="toc">5.6	Use in Patients with Chronic Pulmonary Disease</a></h2>
<h2><a href="#section-5.7" class="toc">5.7	Interactions with CNS Depressants and Illicit Drugs</a></h2>
<h2><a href="#section-5.8" class="toc">5.8	Hypotensive Effect</a></h2>
<h2><a href="#section-5.9" class="toc">5.9	Use in Patients with <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> or <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10	<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11	<span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> Risk</a></h2>
<h2><a href="#section-5.12" class="toc">5.12	Use in Patients with Gastrointestinal Conditions</a></h2>
<h2><a href="#section-5.13" class="toc">5.13	Withdrawal</a></h2>
<h2><a href="#section-5.14" class="toc">5.14	Driving and Operating Heavy Machinery</a></h2>
<h2><a href="#section-5.15" class="toc">5.15	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-5.16" class="toc">5.16	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Post-marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Alcohol, Other Opioids, and Drugs of Abuse</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Monoamine Oxidase Inhibitors</a></h2>
<h2><a href="#section-7.3" class="toc">7.3	CNS Depressants</a></h2>
<h2><a href="#section-7.4" class="toc">7.4	Serotonergic Drugs</a></h2>
<h2><a href="#section-7.5" class="toc">7.5	Mixed Agonist/Antagonist Opioid Analgesics</a></h2>
<h2><a href="#section-7.6" class="toc">7.6	Anticholinergics</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6	Neonatal Withdrawal Syndrome</a></h2>
<h2><a href="#section-8.7" class="toc">8.7	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.8" class="toc">8.8	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse</a></h2>
<h2><a href="#section-9.3" class="toc">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-10.1" class="toc">10.1	Clinical Presentation</a></h2>
<h2><a href="#section-10.2" class="toc">10.2	Management</a></h2>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NON-CLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-13.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1	Orthopedic Surgery – Bunionectomy</a></h2>
<h2><a href="#section-14.2" class="toc">14.2	End-Stage <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Degenerative Joint Disease</span></a></h2>
<h1><a href="#section-15" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">NUCYNTA<span class="Sup">®</span> (tapentadol) is indicated for the management of moderate to severe <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> in adults.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">NUCYNTA<span class="Sup">®</span> oral solution is available in one concentration: 20 mg/mL.</p>
<p>Take care when prescribing and administering NUCYNTA<span class="Sup">®</span> oral solution to avoid dosing errors, which could result in accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Take care to ensure the proper dose is communicated and dispensed. Include the dose in milliliters (mL) and milligrams (mg) when writing prescriptions. Always use the enclosed calibrated oral syringe when administering NUCYNTA<span class="Sup">®</span> oral solution to ensure the dose is measured and administered accurately.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Individualization of Dosage</h2>
<p class="First">As with any opioid drug product, adjust the dosing regimen for each patient individually, taking into account the patient's prior analgesic treatment experience. In the selection of the initial dose of tapentadol, give attention to the following:</p>
<ul>
<li>the total daily dose, potency and specific characteristics of the opioid the patient has been taking previously;</li>
<li>the reliability of the relative potency estimate used to calculate the equivalent morphine sulfate dose needed;</li>
<li>the patient's degree of opioid tolerance;</li>
<li>the general condition and medical status of the patient;</li>
<li>concurrent medications;</li>
<li>the type and severity of the patient's <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>;</li>
<li>risk factors for abuse, addiction or diversion, including a prior history of abuse, addiction or diversion.</li>
</ul>
<p>The following dosing recommendations, therefore, can only be considered suggested approaches to what is actually a series of clinical decisions over time in the management of the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> of each individual patient. Continual re-evaluation of the patient receiving tapentadol is important, with special attention to the maintenance of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> control and the relative incidence of side effects associated with therapy. During chronic therapy, especially for non-cancer-related <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, periodically re-assess the continued need for the use of opioid analgesics.</p>
<p>During periods of changing analgesic requirements, including initial titration, frequent contact is recommended between physician, other members of the healthcare team, the patient, and the caregiver/family. Monitor the patient for signs of respiratory or central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Initiation of Therapy</h2>
<p class="First">The dose is 2.5 mL (equivalent to 50 mg), 3.75 mL (equivalent to 75 mg), or 5 mL (equivalent to 100 mg) every 4 to 6 hours depending upon <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity.</p>
<p>On the first day of dosing, the second dose may be administered as soon as one hour after the first dose, if adequate <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief is not attained with the first dose. Subsequent dosing is 2.5 mL (equivalent to 50 mg), 3.75 mL (equivalent to 75 mg), or 5 mL (equivalent to 100 mg) every 4 to 6 hours and should be adjusted to maintain adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> with acceptable tolerability.</p>
<p>Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not been studied and are not recommended.</p>
<p>NUCYNTA<span class="Sup">®</span> may be given with or without food<span class="Italics"> [see <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Use of NUCYNTA<span class="Sup">®</span> in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not recommended<span class="Italics"> [see <a href="#S5.16">Warnings and Precautions (5.16)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
<p>No dosage adjustment is recommended in patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The safety and efficacy of NUCYNTA<span class="Sup">®</span> has not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Score 10–15) and use in this population is not recommended <span class="Italics">[see <a href="#S5.15">Warnings and Precautions (5.15)</a>]</span>.</p>
<p>Initiate treatment of patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Score 7 to 9) with 50 mg no more frequently than once every 8 hours (maximum of three doses in 24 hours). Further treatment should reflect maintenance of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> with acceptable tolerability, to be achieved by either shortening or lengthening the dosing interval <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>No dosage adjustment is recommended in patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Score 5 to 6) <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5	Elderly Patients</h2>
<p class="First">In general, recommended dosing for elderly patients with normal renal and hepatic function is the same as for younger adult patients with normal renal and hepatic function. Because elderly patients are more likely to have decreased renal and hepatic function, consideration should be given to starting elderly patients with the lower range of recommended doses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.6"></a><a name="section-2.6"></a><p></p>
<h2>2.6	Cessation of Therapy</h2>
<p class="First">When the patient no longer requires therapy with tapentadol, gradually taper the dose to prevent signs and symptoms of withdrawal in the physically dependent patient <span class="Italics">[see <a href="#S5.13">Warnings and Precautions (5.13)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.7"></a><a name="section-2.7"></a><p></p>
<h2>2.7	Instructions for Use</h2>
<p class="First">Concentration and Dispensing: The oral solution contains 20 mg tapentadol per milliliter (mL) and prescriptions should be written in milliliters (mL) and milligrams (mg). An oral syringe is supplied with dose marks corresponding directly to 2.5 mL (equals 50 mg) oral solution, 3.75 mL (equals 75 mg) oral solution, and 5 mL (equals 100 mg) oral solution.</p>
<p>Inform patients of the availability of FDA-approved patient labeling, Instructions for Use, for step-by-step instructions for patients on how to use the medicine bottle and the oral syringe.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">NUCYNTA<span class="Sup">®</span> oral solution: 20 mg/mL oral solution in 100 mL and 200 mL fill bottles with child-resistant closure <span class="Italics">[see <a href="#S11">Description (11)</a> and <a href="#S16">How Supplied/Storage and Handling (16)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">NUCYNTA<span class="Sup">®</span> is contraindicated in:</p>
<ul>
<li>Patients with significant <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span></li>
<li>Patients with acute or severe bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercarbia</span> in an unmonitored setting or in the absence of resuscitative equipment</li>
<li>Patients with known or suspected <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span></li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>) to tapentadol or to any other ingredients of the product <span class="Italics">[see <a href="#S6.2">Adverse Reactions (6.2)</a>]</span>.</li>
<li>Patients who are receiving monoamine oxidase (MAO) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which may result in adverse cardiovascular events <span class="Italics">[see <a href="#S7.2">Drug Interactions (7.2)</a>]</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Abuse Potential</h2>
<p class="First">NUCYNTA<span class="Sup">®</span> contains tapentadol, an opioid agonist and a Schedule II controlled substance. Tapentadol can be abused in a manner similar to other opioid agonists legal or illicit. Opioid agonists are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. Consider these risks when prescribing or dispensing NUCYNTA<span class="Sup">®</span> in situations where there is concern about increased risks of misuse, abuse, or diversion. Concerns about abuse, addiction, and diversion should not, however, prevent the proper management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p>Assess each patient's risk for <span class="product-label-link" type="condition" conceptid="436954" conceptname="Drug abuse">opioid abuse</span> or addiction prior to prescribing NUCYNTA<span class="Sup">®</span>. The risk for <span class="product-label-link" type="condition" conceptid="436954" conceptname="Drug abuse">opioid abuse</span> is increased in patients with a personal or family history of <span class="product-label-link" type="condition" conceptid="4279309" conceptname="Substance abuse">substance abuse</span> (including drug or <span class="product-label-link" type="condition" conceptid="433753" conceptname="Alcohol abuse">alcohol abuse</span> or addiction) or mental illness (e.g., <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">major depression</span>). Patients at increased risk may still be appropriately treated with opioids; however these patients will require intensive monitoring for signs of misuse, abuse, or addiction. Routinely monitor all patients receiving opioids for signs of misuse, abuse, and addiction because these drugs carry a risk for addiction even under appropriate medical use.</p>
<p>Misuse or abuse of NUCYNTA<span class="Sup">®</span> by injecting the oral solution will pose a significant risk that could result in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span><span class="Italics"> [see <a href="#S10">Overdosage (10)</a>].</span></p>
<p>Contact local state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product<span class="Italics"> [see <a href="#S9">Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (9)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Life Threatening <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> is the chief hazard of opioid agonists, including NUCYNTA<span class="Sup">®</span>. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span>, if not immediately recognized and treated, may lead to <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> from opioids is manifested by a reduced urge to breathe and a decreased rate of respiration, often associated with a "sighing" pattern of breathing (deep breaths separated by abnormally long pauses). <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">Carbon dioxide</span> (CO<span class="Sub">2</span>) retention from opioid-induced <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> can exacerbate the sedating effects of opioids. Management of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> may include close observation, supportive measures, and use of opioid antagonists, depending on the patient's clinical status<span class="Italics"> [see <a href="#S10">Overdosage (10)</a>]</span>.</p>
<p>Instruct patients against use by individuals other than the patient for whom NUCYNTA<span class="Sup">®</span> was prescribed and to keep NUCYNTA<span class="Sup">®</span> out of the reach of children, as such inappropriate use may result in fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
<p>Patients with conditions accompanied by <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercarbia</span> or decreased respiratory reserve such as: <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> or <span class="product-label-link" type="condition" conceptid="4307356" conceptname="Cor pulmonale">cor pulmonale</span>, central nervous system (CNS) <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> may be at increased risk for increased airway resistance and decreased respiratory drive to the point of <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> even with usual therapeutic doses of NUCYNTA<span class="Sup">®</span>. Consider the use of alternative non-mu-opioid agonist analgesics and use NUCYNTA<span class="Sup">®</span> only under careful medical supervision at the lowest effective dose in such patients. If <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> occurs, treat the patient for mu-opioid agonist-induced <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span><span class="Italics"> [see <a href="#S10">Overdosage (10)</a>]</span>. To reduce the risk of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, proper dosing of NUCYNTA<span class="Sup">®</span> is essential <span class="Italics">[see <a href="#S2">Dosage and Administration (2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Accidental Exposure</h2>
<p class="First">Accidental ingestion of NUCYNTA<span class="Sup">®</span>, especially in children, can result in a fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of tapentadol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Interactions with Alcohol, Other Opioids, and Drugs of Abuse</h2>
<p class="First">Due to its mu-opioid agonist activity, NUCYNTA<span class="Sup">®</span> may be expected to have additive effects when used in conjunction with alcohol, other opioids, or illicit drugs that cause central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and profound sedation, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> <span class="Italics">[see <a href="#S7.3">Drug Interactions (7.3</a>)]</span>. Instruct patients not to consume alcoholic beverages or use prescription or non-prescription products containing alcohol, other opioids, or drugs of abuse while on NUCYNTA<span class="Sup">®</span> therapy <span class="Italics">[see <a href="#S7.1">Drug Interactions (7.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	Elderly, Cachectic, and Debilitated Patients</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients. Therefore, closely monitor such patients, particularly when NUCYNTA<span class="Sup">®</span> is given concomitantly with other drugs that depress respiration <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	Use in Patients with Chronic Pulmonary Disease</h2>
<p class="First">Monitor for <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> those patients with significant <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> or <span class="product-label-link" type="condition" conceptid="4307356" conceptname="Cor pulmonale">cor pulmonale</span>, and patients having a substantially decreased respiratory reserve, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercarbia</span>, or pre-existing <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, as in these patients, even usual therapeutic doses of NUCYNTA<span class="Sup">®</span> may decrease respiratory drive to the point of <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]. </span>Consider the use of alternative non-opioid analgesics in these patients if possible.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7	Interactions with CNS Depressants and Illicit Drugs</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, and profound sedation, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> may result if NUCYNTA<span class="Sup">®</span> is used concomitantly with other CNS depressants (e.g., sedatives, anxiolytics, hypnotics, neuroleptics, muscle relaxants, other opioids and illicit drugs). When considering the use of NUCYNTA<span class="Sup">®</span> in a patient taking a CNS depressant, assess the duration of use of the CNS depressant and the patient's response, including the degree of tolerance that has developed to <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. Additionally, consider the patient's use, if any, of alcohol and/or illicit drugs that can cause <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. If NUCYNTA<span class="Sup">®</span> therapy is to be initiated in a patient taking a CNS depressant, start with a lower NUCYNTA<span class="Sup">®</span> dose than usual and monitor patients for signs of sedation and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and consider using a lower dose of the concomitant CNS depressant <span class="Italics">[see </span><a href="#S7.3">Drug Interactions (7.3)</a><span class="Italics">]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8	Hypotensive Effect</h2>
<p class="First">NUCYNTA<span class="Sup">®</span> may cause severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. There is an increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics) <span class="Italics">[see <a href="#S7.3">Drug Interactions (7.3)</a>]</span>. Monitor these patients for signs of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> after the dose of NUCYNTA<span class="Sup">®</span>. In patients with circulatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, NUCYNTA<span class="Sup">®</span> may cause vasodilation that can further reduce <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and blood pressure. Avoid the use of NUCYNTA<span class="Sup">®</span> in patients with circulatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9	Use in Patients with <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> or <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></h2>
<p class="First">Monitor patients taking NUCYNTA<span class="Sup">®</span> who may be susceptible to the intracranial effects of CO<span class="Sub">2</span> retention (e.g., those with evidence of <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> or <span class="product-label-link" type="condition" conceptid="4116092" conceptname="Intracranial tumor">brain tumors</span>) for signs of sedation and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. NUCYNTA<span class="Sup">®</span> may reduce respiratory drive, and the resultant CO<span class="Sub">2</span> retention can further increase intracranial pressure. Opioids may also obscure the clinical course in a patient with a <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>.</p>
<p>Avoid the use of NUCYNTA<span class="Sup">®</span> in patients with impaired consciousness or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10	<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h2>
<p class="First">NUCYNTA<span class="Sup">®</span> has not been evaluated in patients with a predisposition to a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder, and such patients were excluded from clinical studies. The active ingredient tapentadol in NUCYNTA<span class="Sup">®</span> may aggravate <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> in patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>, and may induce or aggravate <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in some clinical settings. Monitor patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders for worsened <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control during NUCYNTA<span class="Sup">®</span> therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11	<span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> Risk</h2>
<p class="First">Cases of life-threatening <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> have been reported with the concurrent use of tapentadol and serotonergic drugs. Serotonergic drugs comprise Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, drugs that affect the serotonergic neurotransmitter system (e.g. mirtazapine, trazodone, and tramadol), and drugs that impair metabolism of serotonin (including MAOIs). This may occur within the recommended dose. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> may include mental-status changes (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular aberrations (e.g., <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>) and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>) and can be fatal <span class="Italics">[see <a href="#S7.4">Drug Interactions (7.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.12"></a><a name="section-5.12"></a><p></p>
<h2>5.12	Use in Patients with Gastrointestinal Conditions</h2>
<p class="First">NUCYNTA<span class="Sup">®</span> is contraindicated in patients with GI obstruction, including <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>. The tapentadol in NUCYNTA<span class="Sup">®</span> may cause spasm of the sphincter of Oddi. Monitor patients with <span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">biliary tract disease</span>, including <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>, for worsening symptoms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.13"></a><a name="section-5.13"></a><p></p>
<h2>5.13	Withdrawal</h2>
<p class="First">Withdrawal symptoms may occur if NUCYNTA<span class="Sup">®</span> is discontinued abruptly. These symptoms may include: <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, upper respiratory symptoms, <span class="product-label-link" type="condition" conceptid="4224957" conceptname="Piloerection">piloerection</span>, and rarely, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>. Withdrawal symptoms may be reduced by tapering NUCYNTA<span class="Sup">®</span><span class="Italics"> [see <a href="#S9.3">Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (9.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.14"></a><a name="section-5.14"></a><p></p>
<h2>5.14	Driving and Operating Heavy Machinery</h2>
<p class="First">NUCYNTA<span class="Sup">®</span> may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects of NUCYNTA<span class="Sup">®</span> and know how they will react to the medication.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.15"></a><a name="section-5.15"></a><p></p>
<h2>5.15	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">A study with NUCYNTA<span class="Sup">®</span> in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> showed higher serum concentrations of tapentadol than in those with normal hepatic function. Avoid use of NUCYNTA<span class="Sup">®</span> in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Reduce the dose of NUCYNTA<span class="Sup">®</span> in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#S2.4">Dosage and Administration (2.4)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. Closely monitor patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> for respiratory and central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> when receiving NUCYNTA<span class="Sup">®</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.16"></a><a name="section-5.16"></a><p></p>
<h2>5.16	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Use of NUCYNTA<span class="Sup">®</span> in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not recommended due to accumulation of a metabolite formed by glucuronidation of tapentadol. The clinical relevance of the elevated metabolite is not known <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in more detail in other sections of the labeling:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span> <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>
</li>
<li>Interaction with Alcohol <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>
</li>
<li>Chronic Pulmonary Disease <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>
</li>
<li>Hypotensive Effects <span class="Italics">[see <a href="#S5.8">Warnings and Precautions (5.8)</a>]</span>
</li>
<li>Interactions with Other CNS Depressants <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>
</li>
<li>Drug abuse, addiction, and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> <span class="Italics">[see <a href="#S9.2">Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (9.2</a>, <a href="#S9.3">9.3)</a>]</span>
</li>
<li>Gastrointestinal Effects <span class="Italics">[see <a href="#S5.12">Warnings and Precautions (5.12)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> <span class="Italics">[see <a href="#S5.10">Warnings and Precautions (5.10)]</a></span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> <span class="Italics">[see <a href="#S5.11">Warnings and Precautions (5.11)</a>]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Based on data from nine Phase 2/3 studies that administered multiple doses (seven placebo- and/or active-controlled, one noncontrolled and one Phase 3 active-controlled safety study) the most common adverse reactions (reported by ≥10% in any NUCYNTA<span class="Sup">®</span> dose group) were: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.</p>
<p>The most common reasons for discontinuation due to adverse reactions in the studies described above (reported by ≥1% in any NUCYNTA<span class="Sup">®</span> dose group) were <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (2.6% vs. 0.5%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (2.3% vs. 0.6%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (1.4% vs. 0.2%), <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (1.3% vs. 0.2%) and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (0.9% vs. 0.2%) for NUCYNTA<span class="Sup">®</span>- and placebo-treated patients, respectively.</p>
<p>Seventy-six percent of NUCYNTA<span class="Sup">®</span>-treated patients from the nine studies experienced adverse events.</p>
<p>NUCYNTA<span class="Sup">®</span> was studied in multiple-dose, active- or placebo-controlled studies, or noncontrolled studies (n = 2178), in single-dose studies (n = 870), in open-label study extension (n = 483) and in Phase 1 studies (n = 597). Of these, 2034 patients were treated with doses of 50 mg to 100 mg of NUCYNTA<span class="Sup">®</span> dosed every 4 to 6 hours.</p>
<p>The data described below reflect exposure to NUCYNTA<span class="Sup">®</span> in 3161 patients, including 449 exposed for 45 days. NUCYNTA<span class="Sup">®</span> was studied primarily in placebo- and active-controlled studies (n = 2266, and n = 2944, respectively). The population was 18 to 85 years old (mean age 46 years), 68% were female, 75% white and 67% were postoperative. Most patients received NUCYNTA<span class="Sup">®</span> doses of 50 mg, 75 mg, or 100 mg every 4 to 6 hours.</p>
<table width="90%">
<caption><span>Table 1	Adverse Reactions Reported by ≥1% of NUCYNTA<span class="Sup">®</span>-Treated Patients In Seven Phase 2/3 Placebo- and/or Oxycodone-Controlled, One Non-controlled, and One Phase 3 Oxycodone-Controlled Safety, Multiple-Dose Clinical Studies</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule" align="left">System/Organ Class<br>  MedDRA Preferred Term</th>
<th class="Lrule" align="center">NUCYNTA<span class="Sup">®</span><br>21 mg – 120 mg<br>(n = 2178)<br>%</th>
<th class="Lrule Rrule" align="center">Placebo<br>(n = 619)<br>%</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Lrule" align="center">30</td>
<td class="Lrule Rrule" align="center">13</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule" align="center">18</td>
<td class="Lrule Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Lrule" align="center">8</td>
<td class="Lrule Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Lrule" align="center">4</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Lrule" align="center">2</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">General disorders and administration site conditions</td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Lrule" align="center">3</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4141161" conceptname="Hot">Feeling hot</span></td>
<td class="Lrule" align="center">1</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td class="Lrule" align="center">1</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Lrule" align="center">1</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Lrule" align="center">1</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Metabolism and nutrition disorders</td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></td>
<td class="Lrule" align="center">2</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Lrule" align="center">24</td>
<td class="Lrule Rrule" align="center">8</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Lrule" align="center">15</td>
<td class="Lrule Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td class="Lrule" align="center">1</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></td>
<td class="Lrule" align="center">1</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Psychiatric disorders</td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Lrule" align="center">2</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusional state</span></td>
<td class="Lrule" align="center">1</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal dreams</span></td>
<td class="Lrule" align="center">1</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td class="Lrule" align="center">1</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Skin and subcutaneous tissue disorders</td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Lrule" align="center">5</td>
<td class="Lrule Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span></td>
<td class="Lrule" align="center">3</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4172849" conceptname="Generalized pruritus">Pruritus generalized</span></td>
<td class="Lrule" align="center">3</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Lrule" align="center">1</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot flush</span></td>
<td class="Lrule" align="center">1</td>
<td class="Lrule Rrule" align="center">&lt;1</td>
</tr>
</tbody>
</table>
<p>The following adverse drug reactions occurred in less than 1% of NUCYNTA<span class="Sup">®</span>-treated patients in the pooled safety data from nine Phase 2/3 clinical studies:</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>: </span><span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">heart rate increased</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">heart rate decreased</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span>: </span><span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="4010028" conceptname="Impaired gastric emptying">impaired gastric emptying</span></p>
<p><span class="Bold">General disorders and administration site conditions: </span><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="441260" conceptname="Drug withdrawal">drug withdrawal syndrome</span>, <span class="product-label-link" type="condition" conceptid="4012565" conceptname="Feeling intoxicated">feeling drunk</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span></p>
<p><span class="Bold">Investigations: </span>gamma-glutamyltransferase increased, <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> increased, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> increased</p>
<p><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span>: </span>involuntary muscle contractions, <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">sensation of heaviness</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">disturbance in attention</span>, sedation, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">depressed level of consciousness</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4142895" conceptname="Near syncope">presyncope</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>,  <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">coordination abnormal</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span></p>
<p><span class="Bold">Psychiatric disorders: </span><span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoric mood</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">thinking abnormal</span></p>
<p><span class="Bold">Renal and urinary disorders: </span><span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">urinary hesitation</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">pollakiuria</span></p>
<p><span class="Bold">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>: </span>oxygen saturation decreased, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span></p>
<p><span class="Bold">Skin and subcutaneous tissue disorders: </span><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span>: </span><span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">blood pressure decreased</span></p>
<p>In the pooled safety data, the overall incidence of adverse reactions increased with increased dose of NUCYNTA<span class="Sup">®</span>, as did the percentage of patients with adverse reactions of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Post-marketing Experience</h2>
<p class="First">The following additional adverse reactions have been identified during post-approval use of NUCYNTA<span class="Sup">®</span>. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>: </span><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>: </span><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></p>
<p><span class="Bold">Psychiatric disorders: </span><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attack</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>: </span><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span></p>
<p><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> have been reported very rarely with ingredients contained in NUCYNTA<span class="Sup">®</span>. Advise patients how to recognize such reactions and when to seek medical attention.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">NUCYNTA<span class="Sup">®</span> is mainly metabolized by glucuronidation. The following substances have been included in a set of interaction studies without any clinically significant finding: acetaminophen, acetylsalicylic acid, naproxen and probenecid <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>The pharmacokinetics of tapentadol were not affected when gastric pH or gastrointestinal motility were increased by omeprazole and metoclopramide, respectively <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Alcohol, Other Opioids, and Drugs of Abuse</h2>
<p class="First">Due to its mu-opioid agonist activity, NUCYNTA® may be expected to have additive effects when used in conjunction with alcohol, other opioids, or illicit drugs that cause central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and profound sedation, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Instruct patients not to consume alcoholic beverages or use prescription or non-prescription products containing alcohol, other opioids, or drugs of abuse while on NUCYNTA<span class="Sup">®</span> therapy <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Monoamine Oxidase Inhibitors</h2>
<p class="First">NUCYNTA<span class="Sup">®</span> is contraindicated in patients who are receiving monoamine oxidase (MAO) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which may result in adverse cardiovascular events <span class="Italics">[see <a href="#S4">Contraindications (4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3	CNS Depressants</h2>
<p class="First">Concurrent use of NUCYNTA<span class="Sup">®</span> and other central nervous system (CNS) depressants including sedatives or hypnotics, general anesthetics, phenothiazines, tranquilizers, and alcohol can increase the risk of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, profound sedation or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. Monitor patients receiving CNS depressants and NUCYNTA<span class="Sup">®</span> for signs of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. When such combined therapy is contemplated, start NUCYNTA<span class="Sup">®</span> at 1/3 to 1/2 of the usual dosage and consider using a lower dose of the concomitant CNS depressant <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4	Serotonergic Drugs</h2>
<p class="First">There have been post-marketing reports of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with the concomitant use of tapentadol and serotonergic drugs (e.g., SSRIs and SNRIs). Caution is advised when NUCYNTA<span class="Sup">®</span> is co-administered with other drugs that may affect serotonergic neurotransmitter systems such as SSRIs, SNRIs, MAOIs, and triptans. If concomitant treatment of NUCYNTA<span class="Sup">®</span> with a drug affecting the serotonergic neurotransmitter system is clinically warranted, careful observation of the patient is advised <span class="Italics">[see <a href="#S5.11">Warning and Precautions (5.11)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.5"></a><a name="section-7.5"></a><p></p>
<h2>7.5	Mixed Agonist/Antagonist Opioid Analgesics</h2>
<p class="First">The concomitant use of NUCYNTA<span class="Sup">®</span> with mixed agonist/antagonists (e.g., butorphanol,  nalbuphine, and pentazocine) and partial agonists (e.g., buprenorphine) may precipitate withdrawal symptoms. Avoid the use of agonist/antagonists and partial agonists with NUCYNTA<span class="Sup">®</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.6"></a><a name="section-7.6"></a><p></p>
<h2>7.6	Anticholinergics</h2>
<p class="First">The use of NUCYNTA<span class="Sup">®</span> with anticholinergic products may increase the risk of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> and/or severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, which may lead to <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C: There are no adequate and well-controlled studies of NUCYNTA<span class="Sup">®</span> in pregnant women. NUCYNTA<span class="Sup">®</span> should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>Tapentadol HCl was evaluated for teratogenic effects in pregnant rats and rabbits following intravenous and subcutaneous exposure during the period of embryofetal organogenesis. When tapentadol was administered twice daily by the subcutaneous route in rats at dose levels of 10, 20, or 40 mg/kg/day [producing up to 1 times the plasma exposure at the maximum recommended human dose (MRHD) of 700 mg/day based on an area under the time-curve (AUC) comparison], no teratogenic effects were observed. Evidence of embryofetal toxicity included transient delays in skeletal maturation (i.e. reduced ossification) at the 40 mg/kg/day dose which was associated with significant maternal toxicity. Administration of tapentadol HCl in rabbits at doses of 4, 10, or 24 mg/kg/day by subcutaneous injection [producing 0.2, 0.6, and 1.85 times the plasma exposure at the MRHD based on an AUC comparison] revealed embryofetal toxicity at doses ≥10 mg/kg/day. Findings included reduced fetal viability, skeletal delays and other variations. In addition, there were multiple malformations including <span class="product-label-link" type="condition" conceptid="4218764" conceptname="Gastroschisis">gastroschisis</span>/thoracogastroschisis, amelia/<span class="product-label-link" type="condition" conceptid="73307" conceptname="Transverse deficiency of lower limb">phocomelia</span>, and <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> at doses ≥10 mg/kg/day and above, and ablepharia, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, and <span class="product-label-link" type="condition" conceptid="4283381" conceptname="Spina bifida">spina bifida</span> at the high dose of 24 mg/kg/day. Embryofetal toxicity, including malformations, may be secondary to the significant maternal toxicity observed in the study.</p>
<p>In a study of pre- and postnatal development in rats, oral administration of tapentadol at doses of 20, 50, 150, or 300 mg/kg/day to pregnant and lactating rats during the late gestation and early postnatal period [resulting in up to 1.7 times the plasma exposure at the MRHD on an AUC basis] did not influence physical or reflex development, the outcome of neurobehavioral tests or reproductive parameters. Treatment-related <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delay</span> was observed, including incomplete ossification, and significant reductions in pup body weights and body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gains</span> at doses associated with maternal toxicity (150 mg/kg/day and above). At maternal tapentadol doses ≥150 mg/kg/day, a dose-related increase in pup mortality was observed through postnatal Day 4.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="S8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">NUCYNTA<span class="Sup">®</span> is not for use in women during and immediately prior to labor. Occasionally, opioid analgesics may prolong labor by temporarily reducing the strength, duration, and frequency of uterine contractions. However, these effects are not consistent and may be offset by an increased rate of cervical dilatation which tends to shorten labor.</p>
<p>Opioids cross the placenta and may produce <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and psychophysiologic effects in neonates. Closely observe neonates whose mothers received opioid analgesics during labor for signs of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. An opioid antagonist, such as naloxone, should be available for reversal of opioid-induced <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the neonate in such situations.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">There is insufficient/limited information on the excretion of tapentadol in human or animal breast milk. Physicochemical and available pharmacodynamic/toxicological data on tapentadol point to excretion in breast milk and risk to the breastfeeding child cannot be excluded.</p>
<p>Because of the potential for adverse reactions in nursing infants from NUCYNTA<span class="Sup">®</span>, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
<p>Withdrawal symptoms can occur in breast-feeding infants when maternal administration of NUCYNTA<span class="Sup">®</span> is stopped.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of NUCYNTA<span class="Sup">®</span> in pediatric patients less than 18 years of age have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of patients in Phase 2/3 double-blind, multiple-dose clinical studies of NUCYNTA<span class="Sup">®</span>, 19% were 65 and over, while 5% were 75 and over. No overall differences in effectiveness were observed between these patients and younger patients. The rate of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> was higher in subjects greater than or equal to 65 years than those less than 65 years (12% vs. 7%).</p>
<p>In general, recommended dosing for elderly patients with normal renal and hepatic function is the same as for younger adult patients with normal renal and hepatic function. Because elderly patients are more likely to have decreased renal and hepatic function, consideration should be given to starting elderly patients with the lower range of recommended doses <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.6"></a><p></p>
<h2>8.6	Neonatal Withdrawal Syndrome</h2>
<p class="First">Chronic maternal use of NUCYNTA<span class="Sup">®</span> during pregnancy can affect the neonate with subsequent withdrawal signs. Neonatal withdrawal syndrome presents as <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> and abnormal sleep pattern, high pitched cry, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and failure to gain weight. The onset, duration and severity of neonatal withdrawal syndrome vary based on the drug used, duration of use, the dose of last maternal use, and rate of elimination drug by the newborn. Neonatal opioid withdrawal syndrome may be life-threatening and should be treated according to protocols developed by neonatology experts.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.7"></a><p></p>
<h2>8.7	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The safety and effectiveness of NUCYNTA<span class="Sup">®</span> has not been established in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CLCR &lt;30 mL/min). Use of NUCYNTA<span class="Sup">®</span> in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not recommended due to accumulation of a metabolite formed by glucuronidation of tapentadol. The clinical relevance of the elevated metabolite is not known <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.8"></a><a name="section-8.8"></a><p></p>
<h2>8.8	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Administration of tapentadol resulted in higher exposures and serum levels of tapentadol in subjects with impaired hepatic function compared to subjects with normal hepatic function <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. The dose of NUCYNTA<span class="Sup">®</span> should be reduced in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Score 7 to 9) <span class="Italics">[see <a href="#S2.4">Dosage and Administration (2.4)</a>]</span>.</p>
<p>Use of NUCYNTA<span class="Sup">®</span> is not recommended in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Score 10 to 15) <span class="Italics">[see <a href="#S5.15">Warnings and Precautions (5.15)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="S9"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="S9.1"></a><a name="section-9.1"></a><p></p>
<h2>9.1 Controlled Substance</h2>
<p class="First">NUCYNTA<span class="Sup">®</span> contains tapentadol, a Schedule II controlled substance with a high potential for abuse similar to fentanyl, methadone, morphine, oxycodone, and oxymorphone. NUCYNTA<span class="Sup">®</span> is subject to misuse, abuse, addiction, and criminal diversion <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="S9.2"></a><a name="section-9.2"></a><p></p>
<h2>9.2 Abuse</h2>
<p class="First">All patients treated with opioids require careful monitoring for signs of abuse and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use.</p>
<p>Drug abuse is the intentional non-therapeutic use of an over-the-counter or prescription drug, even once, for its rewarding psychological or physiological effects. Drug abuse includes, but is not limited to the following examples:  the use of  a prescription or over-the-counter drug to get "high", or the use of steroids for performance enhancement and muscle build up.</p>
<p><span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use and include: a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, increased tolerance, and sometimes a physical withdrawal.</p>
<p>"Drug seeking" behavior is very common in addicts, and drug abusers. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated claims of loss of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s). "Healthcare professional shopping" (visiting multiple prescribers) to obtain additional prescriptions is common among drug abusers, people suffering from untreated addiction and criminals seeking drugs to sell.</p>
<p>Abuse and addiction are separate and distinct from physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance. Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> in all addicts. In addition, abuse of opioids can occur in the absence of true addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances. </p>
<p>NUCYNTA<span class="Sup">®</span> can be diverted for non-medical use into illicit channels of distribution. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by law, is strongly advised.</p>
<p>Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="S9.3"></a><a name="section-9.3"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Both tolerance and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> can develop during chronic opioid therapy. Tolerance is the need for increasing doses of opioids to maintain a defined effect such as <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> (in the absence of disease progression or other external factors). Tolerance may occur to both the desired and undesired effects of drugs, and may develop at different rates for different effects.</p>
<p>Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> results in withdrawal symptoms after abrupt discontinuation or a significant dose reduction of a drug. Withdrawal also may be precipitated through the administration of drugs with opioid antagonist activity, e.g., naloxone, nalmefene, or mixed agonist/antagonist analgesics (pentazocine, butorphanol, buprenorphine, nalbuphine). Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> may not occur to a clinically significant degree until after several days to weeks of continued opioid usage. Some or all of the following can characterize this syndrome: <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, perspiration, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4224957" conceptname="Piloerection">piloerection</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, or heart rate. Withdrawal symptoms may be reduced by tapering NUCYNTA<span class="Sup">®</span>.</p>
<p>Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal symptoms <span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1</a>, <a href="#S8.2">8.2</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S10.1"></a><a name="section-10.1"></a><p></p>
<h2>10.1	Clinical Presentation</h2>
<p class="First">Acute overdosage with opioids can be manifested by <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, skeletal muscle <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">constricted pupils</span>, and sometimes <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Marked <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> rather than <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> may be seen due to severe <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> situations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S10.2"></a><a name="section-10.2"></a><p></p>
<h2>10.2	Management</h2>
<p class="First">In case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, priorities are the re-establishment of a patent and protected airway and institution of assisted or controlled ventilation if needed. Employ other supportive measures (including oxygen, vasopressors) in the management of circulatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> as indicated. <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span> or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> will require advanced life support techniques.</p>
<p>The opioid antagonists, naloxone or nalmefene, are specific antidotes to <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> resulting from opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Opioid antagonists should not be administered in the absence of clinically significant respiratory or circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> secondary to tapentadol <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Such agents should be administered cautiously to patients who are known, or suspected to be, physically dependent on NUCYNTA<span class="Sup">®</span>. In such cases, an abrupt or complete reversal of opioid effects may precipitate an acute withdrawal syndrome.</p>
<p>Because the duration of reversal would be expected to be less than the duration of action of tapentadol in NUCYNTA<span class="Sup">®</span>, carefully monitor the patient until spontaneous respiration is reliably re-established. If the response to opioid antagonists is suboptimal or not sustained, additional antagonist should be given as directed in the product's prescribing information.</p>
<p>In an individual physically dependent on opioids, administration of an opioid receptor antagonist may precipitate an acute withdrawal. The severity of the withdrawal produced will depend on the degree of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and the dose of the antagonist administered. If a decision is made to treat serious <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the physically dependent patient, administration of the antagonist should be begun with care and by titration with smaller than usual doses of the antagonist.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">NUCYNTA<span class="Sup">®</span> (tapentadol) is a mu-opioid receptor agonist, supplied in a liquid solution for oral administration. The chemical name is 3-[(1<span class="Italics">R</span>,2<span class="Italics">R</span>)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol monohydrochloride. The structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e921054f-b3f1-4624-8edd-f6628c6f0fd9&amp;name=nucynta-01.jpg"></div>
<p>The molecular weight of tapentadol HCl is 257.80, and the molecular formula is C<span class="Sub">14</span>H<span class="Sub">23</span>NO•HCl. The n-octanol:water partition coefficient log P value is 2.87. The pKa values are 9.34 and 10.45.</p>
<p>NUCYNTA<span class="Sup">®</span> (tapentadol) oral solution is supplied as a clear, colorless solution and contains 20 mg/mL of tapentadol (corresponding to 23 mg/mL of tapentadol hydrochloride) and the following inactive ingredients: citric acid monohydrate, purified water, raspberry flavor, sodium hydroxide, and sucralose.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Tapentadol is a centrally-acting synthetic analgesic. The exact mechanism of action is unknown. Although the clinical relevance is unclear, preclinical studies have shown that tapentadol is a mu-opioid receptor (MOR) agonist and a norepinephrine reuptake inhibitor (NRI). <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span> in animal models is derived from both of these properties.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Tapentadol is 18 times less potent than morphine in binding to the human mu-opioid receptor and is 2–3 times less potent in producing <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> in animal models. Tapentadol has been shown to inhibit norepinephrine reuptake in the brains of rats resulting in increased norepinephrine concentrations. In preclinical models, the analgesic activity due to the mu-opioid receptor agonist activity of tapentadol can be antagonized by selective mu-opioid antagonists (e.g., naloxone), whereas the norepinephrine reuptake inhibition is sensitive to norepinephrine modulators. Tapentadol exerts its <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effects</span> without a pharmacologically active metabolite.</p>
<p>Concentration-Efficacy Relationships</p>
<p>The minimum effective plasma concentration of tapentadol for <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> varies widely among patients, especially among patients who have been previously treated with agonist opioids. </p>
<p>Concentration-Adverse Experience Relationships</p>
<p>There is a general relationship between increasing opioid plasma concentration and increasing frequency of adverse experiences such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, CNS effects, and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
<p>Effects on the cardiovascular system</p>
<p>There was no effect of therapeutic and supratherapeutic doses of tapentadol on the QT interval. In a randomized, double-blind, placebo- and positive-controlled crossover study, healthy subjects were administered five consecutive doses of NUCYNTA<span class="Sup">®</span> 100 mg every 6 hours, NUCYNTA<span class="Sup">®</span> 150 mg every 6 hours, placebo and a single oral dose of moxifloxacin. Similarly, NUCYNTA<span class="Sup">®</span> had no relevant effect on other ECG parameters (heart rate, PR interval, QRS duration, T-wave or U-wave morphology).</p>
<p>Tapentadol produces peripheral vasodilation which may result in <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>.</p>
<p>Effects on the Central Nervous System (CNS)</p>
<p>The principal therapeutic action of tapentadol is <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. Tapentadol causes <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, in part by a direct effect on the brainstem respiratory centers. The <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> involves a reduction in the responsiveness of the brain stem respiratory centers to both increases in <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> and electrical stimulation. Tapentadol depresses the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex by direct effect on the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> center in the medulla. </p>
<p>Tapentadol causes <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, even in total darkness. Pinpoint pupils are a sign of opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origin may produce similar findings). Marked <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> rather than <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> may be seen with <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> situations <span class="Italics">[see <a href="#S10">Overdosage (10)</a>]</span>. Other effects of tapentadol include anxiolysis, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, and <span class="product-label-link" type="condition" conceptid="4035488" conceptname="Relaxed">feeling of relaxation</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and changes in mood.</p>
<p>Effects on the Gastrointestinal Tract and on Other Smooth Muscle</p>
<p>Gastric, biliary and pancreatic secretions are decreased by tapentadol. Tapentadol causes a reduction in motility and is associated with an increase in tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone is increased to the point of spasm. The end result is <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. Tapentadol can cause a marked increase in biliary tract pressure as a result of spasm of the sphincter of Oddi, and transient elevations in serum amylase. Tapentadol may also cause spasm of the sphincter of the urinary bladder.</p>
<p>Effects on the Endocrine System</p>
<p>Opioid agonists have been shown to have a variety of effects on the secretion of hormones. Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans. They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon.</p>
<p>Effects on the Immune System</p>
<p>Opioids have been shown to have a variety of effects on components of the immune system in <span class="Italics">in vitro</span> and animal models. The clinical significance of these findings is unknown.</p>
<p>CNS Depressant/Alcohol Interaction</p>
<p>Additive pharmacodynamic effects may be expected when NUCYNTA<span class="Sup">®</span> is used in conjunction with alcohol, other opioids, or illicit drugs that cause central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Absorption</p>
<p>The mean absolute bioavailability after single-dose administration (fasting) of  NUCYNTA<span class="Sup">®</span> is approximately 32% due to extensive first-pass metabolism. Maximum serum concentrations of tapentadol are typically observed at around 1.25 hours after dosing.</p>
<p>Dose-proportional increases in the C<span class="Sub">max</span> and AUC values of tapentadol have been observed over the 50 to 150 mg dose range.</p>
<p>A multiple (every 6 hour) dose study with doses ranging from 75 to 175 mg tapentadol showed a mean accumulation factor of 1.6 for the parent drug and 1.8 for the major metabolite tapentadol-O-glucuronide, which are primarily determined by the dosing interval and apparent half-life of tapentadol and its metabolite.</p>
<p>Food Effect</p>
<p>The AUC and C<span class="Sub">max</span> increased by 25% and 16%, respectively, when NUCYNTA<span class="Sup">®</span> was administered after a high-fat, high-calorie breakfast. NUCYNTA<span class="Sup">®</span> may be given with or without food.</p>
<p>Distribution</p>
<p>Tapentadol is widely distributed throughout the body. Following intravenous administration, the volume of distribution (Vz) for tapentadol is 540 +/- 98 L. The plasma protein binding is low and amounts to approximately 20%.</p>
<p>Metabolism and Elimination</p>
<p>In humans, about 97% of the parent compound is metabolized. Tapentadol is mainly metabolized via Phase 2 pathways, and only a small amount is metabolized by Phase 1 oxidative pathways. The major pathway of tapentadol metabolism is conjugation with glucuronic acid to produce glucuronides. After oral administration approximately 70% (55% O-glucuronide and 15% sulfate of tapentadol) of the dose is excreted in urine in the conjugated form. A total of 3% of drug was excreted in urine as unchanged drug. Tapentadol is additionally metabolized to N-desmethyl tapentadol (13%) by CYP2C9 and CYP2C19 and to hydroxy tapentadol (2%) by CYP2D6, which are further metabolized by conjugation. Therefore, drug metabolism mediated by cytochrome P450 system is of less importance than phase 2 conjugation.</p>
<p>None of the metabolites contribute to the analgesic activity.</p>
<p>Tapentadol and its metabolites are excreted almost exclusively (99%) via the kidneys. The terminal half-life is on average 4 hours after oral administration. The total clearance is 1530 +/- 177 mL/min.</p>
<p>Special Populations</p>
<p><span class="Italics">Geriatric Patients </span></p>
<p>The mean exposure (AUC) to tapentadol was similar in elderly subjects compared to young adults, with a 16% lower mean C<span class="Sub">max</span> observed in the elderly subject group compared to young adult subjects.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>AUC and C<span class="Sub">max</span> of tapentadol were comparable in subjects with varying degrees of renal function (from normal to severely impaired). In contrast, increasing exposure (AUC) to tapentadol-O-glucuronide was observed with increasing degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. In subjects with mild (CL<span class="Sub">CR</span> = 50 to &lt;80 mL/min), moderate (CL<span class="Sub">CR</span> = 30 to &lt;50 mL/min), and severe (CL<span class="Sub">CR</span> = &lt;30 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the AUC of tapentadol-O-glucuronide was 1.5-, 2.5-, and 5.5-fold higher compared with normal renal function, respectively.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>Administration of NUCYNTA<span class="Sup">®</span> resulted in higher exposures and serum levels to tapentadol in subjects with impaired hepatic function compared to subjects with normal hepatic function. The ratio of tapentadol pharmacokinetic parameters for the mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> group (Child-Pugh Score 5 to 6) and moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> group (Child-Pugh Score 7 to 9) in comparison to the normal hepatic function group were 1.7 and 4.2, respectively, for AUC; 1.4 and 2.5, respectively, for C<span class="Sub">max</span>; and 1.2 and 1.4, respectively, for t<span class="Sub">1/2</span>. The rate of formation of tapentadol-O-glucuronide was lower in subjects with increased liver impairment.</p>
<p>Pharmacokinetic Drug Interactions</p>
<p>Tapentadol is mainly metabolized by Phase 2 glucuronidation, a high capacity/low affinity system; therefore, clinically relevant interactions caused by Phase 2 metabolism are unlikely to occur. Naproxen and probenecid increased the AUC of tapentadol by 17% and 57%, respectively. These changes are not considered clinically relevant and no change in dose is required.</p>
<p>No changes in the pharmacokinetic parameters of tapentadol were observed when acetaminophen and acetylsalicylic acid were given concomitantly.</p>
<p><span class="Italics">In vitro </span>studies did not reveal any potential of tapentadol to either inhibit or induce cytochrome P450 enzymes. Furthermore, a minor amount of NUCYNTA<span class="Sup">®</span> is metabolized via the oxidative pathway. Thus, clinically relevant interactions mediated by the cytochrome P450 system are unlikely to occur.</p>
<p>The pharmacokinetics of tapentadol were not affected when gastric pH or gastrointestinal motility were increased by omeprazole and metoclopramide, respectively.</p>
<p>Plasma protein binding of tapentadol is low (approximately 20%). Therefore, the likelihood of pharmacokinetic drug-drug interactions by displacement from the protein binding site is low.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-13"></a><p></p>
<h1>13 NON-CLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenesis</p>
<p>Tapentadol was administered to rats (diet) and mice (oral gavage) for two years.</p>
<p>In mice, tapentadol HCl was administered by oral gavage at dosages of 50, 100 and 200 mg/kg/day for 2 years (up to 0.2 times the plasma exposure at the maximum recommended human dose [MRHD] on an area under the time-curve [AUC] basis). No increase in tumor incidence was observed at any dose level.</p>
<p>In rats, tapentadol HCl was administered in diet at dosages of 10, 50, 125 and 250 mg/kg/day for two years (up to 0.2 times in the male rats and 0.6 times in the female rats the MRHD on an AUC basis). No increase in tumor incidence was observed at any dose level.</p>
<p>Mutagenesis</p>
<p>Tapentadol did not induce gene mutations in bacteria, but was clastogenic with metabolic activation in a chromosomal aberration test in V79 cells. The test was repeated and was negative in the presence and absence of metabolic activation. The one positive result for tapentadol was not confirmed <span class="Italics">in vivo</span> in rats, using the two endpoints of chromosomal aberration and unscheduled DNA synthesis, when tested up to the maximum tolerated dose.</p>
<p>Impairment of Fertility</p>
<p>Tapentadol HCl was administered intravenously to male or female rats at dosages of 3, 6, or 12 mg/kg/day (representing exposures of up to approximately 0.4 times the exposure at the MRHD on an AUC basis, based on extrapolation from toxicokinetic analyses in a separate 4-week intravenous study in rats). Tapentadol did not alter fertility at any dose level. Maternal toxicity and adverse effects on embryonic development, including decreased number of implantations, decreased numbers of live conceptuses, and increased pre- and post-implantation losses occurred at dosages ≥6 mg/kg/day. </p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="S13.2"></a><a name="section-13.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">In toxicological studies with tapentadol, the most common systemic effects of tapentadol were related to the mu-opioid receptor agonist and norepinephrine reuptake inhibition pharmacodynamic properties of the compound. Transient, dose-dependent and predominantly CNS-related findings were observed, including impaired respiratory function and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, the latter occurring in the dog at plasma levels (C<span class="Sub">max</span>) which are in the range associated with the maximum recommended human dose (MRHD).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The efficacy and safety of NUCYNTA<span class="Sup">®</span> in the treatment of moderate to severe <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> has been established in two randomized, double-blind, placebo- and active-controlled studies of moderate to severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from first metatarsal bunionectomy and end-stage <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">degenerative joint disease</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-14.1"></a><p></p>
<h2>14.1	Orthopedic Surgery – Bunionectomy</h2>
<p class="First">A randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study demonstrated the efficacy of 50 mg, 75 mg, and 100 mg NUCYNTA<span class="Sup">®</span> given every 4 to 6 hours for 72 hours in patients aged 18 to 80 years experiencing moderate to severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> following unilateral, first metatarsal bunionectomy surgery. Patients who qualified for the study with a baseline <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score of ≥4 on an 11-point rating scale ranging from 0 to 10 were randomized to 1 of 5 treatments. Patients were allowed to take a second dose of study medication as soon as 1 hour after the first dose on study Day 1, with subsequent dosing every 4 to 6 hours. If rescue analgesics were required, the patients were discontinued for lack of efficacy. Efficacy was evaluated by comparing the sum of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity difference over the first 48 hours (SPID48) versus placebo. NUCYNTA<span class="Sup">®</span> at each dose provided a greater reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> compared to placebo based on SPID48 values. </p>
<p>For various degrees of improvement from baseline to the 48-hour endpoint, Figure 1 shows the fraction of patients achieving that level of improvement. The figures are cumulative, such that every patient that achieves a 50% reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from baseline is included in every level of improvement below 50%. Patients who did not complete the 48-hour observation period in the study were assigned 0% improvement.</p>
<table class="Noautorules" width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless">
<tr><td align="center"><span class="Bold">Figure 1:    Percentage of Patients Achieving Various Levels of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Relief as Measured by <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Severity at 48 Hours Compared to Baseline- Post Operative Bunionectomy</span></td></tr>
<tr><td align="center">
<a name="fig1"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e921054f-b3f1-4624-8edd-f6628c6f0fd9&amp;name=nucynta-02.jpg">
</td></tr>
</tbody>
</table>
<p>The proportions of patients who showed reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity at 48 hours of 30% or greater, or 50% or greater were significantly higher in patients treated with NUCYNTA<span class="Sup">®</span> at each dose versus placebo. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-14.2"></a><p></p>
<h2>14.2	End-Stage <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Degenerative Joint Disease</span></h2>
<p class="First">A randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study evaluated the efficacy and safety of 50 mg and 75 mg NUCYNTA<span class="Sup">®</span> given every 4 to 6 hours during waking hours for 10 days in patients aged 18 to 80 years, experiencing moderate to severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from end stage <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">degenerative joint disease</span> of the hip or knee, defined as a 3-day mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score of ≥5 on an 11-point <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity scale, ranging from 0 to 10. <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> scores were assessed twice daily and assessed the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> the patient had experienced over the previous 12 hours. Patients were allowed to continue non-opioid analgesic therapy for which they had been on a stable regimen before screening throughout the study. Eighty-three percent (83%) of patients in the tapentadol treatment groups and the placebo group took such <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> during the study. The 75 mg treatment group was dosed at 50 mg for the first day of the study, followed by 75 mg for the remaining nine days. Patients requiring rescue analgesics other than study medication were discontinued for lack of efficacy. Efficacy was evaluated by comparing the sum of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity difference (SPID) versus placebo over the first five days of treatment. NUCYNTA<span class="Sup">®</span> 50 mg and 75 mg provided improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> compared with placebo based on the 5-Day SPID.</p>
<p>For various degrees of improvement from baseline to the Day 5 endpoint, Figure 2 shows the fraction of patients achieving that level of improvement. The figures are cumulative, such that every patient that achieves a 50% reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from baseline is included in every level of improvement below 50%. Patients who did not complete the 5-day observation period in the study were assigned 0% improvement.</p>
<table class="Noautorules" width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless">
<tr><td align="center"><span class="Bold">Figure 2:    Percentage of Patients Achieving Various Levels of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Relief as Measured by Average <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Severity for the Previous 12 hours, Measured on Study Day 5 Compared to Baseline -- End Stage <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Degenerative Joint Disease</span></span></td></tr>
<tr><td align="center">
<a name="fig2"></a><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e921054f-b3f1-4624-8edd-f6628c6f0fd9&amp;name=nucynta-03.jpg">
</td></tr>
</tbody>
</table>
<p>The proportions of patients who showed reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity at 5 days of 30% or greater, or 50% or greater were significantly higher in patients treated with NUCYNTA<span class="Sup">®</span> at each dose versus placebo. </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-15"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">NUCYNTA<span class="Sup">®</span> oral solution, 20 mg/mL, is available as a clear, colorless solution.</p>
<p>Supplied with calibrated syringe:<br><br>Bottles of 100 mL (NDC 50458-817-01)<br><br>Bottles of 200 mL (NDC 50458-817-02)</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15.1"></a><p></p>
<p class="First"><span class="Bold">Storage and Handling</span></p>
<p>Store up to 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Store the oral solution bottle upright after opening.</p>
<p>Keep NUCYNTA<span class="Sup">®</span> in a secure place out of reach of children.</p>
<p>NUCYNTA<span class="Sup">®</span> oral solution that is no longer needed should be destroyed by <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> down the toilet.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved patient labeling (<a href="#MEDGUIDE">Medication Guide</a> and <a href="#INSTRUCT">Instructions for Use</a>).</p>
<p>Inform patients of the availability of a Medication Guide and Instructions for Use, and instruct them to read the Medication Guide and Instructions for Use prior to taking NUCYNTA<span class="Sup">®</span> oral solution.</p>
<p>Instruct patients to take NUCYNTA<span class="Sup">®</span> oral solution only as prescribed.</p>
<p>Abuse Potential</p>
<p>Inform patients that NUCYNTA<span class="Sup">®</span> contains tapentadol, a Schedule II controlled substance that is subject to abuse. Instruct patients not to share NUCYNTA<span class="Sup">®</span> with others and to take steps to protect NUCYNTA<span class="Sup">®</span> from <span class="product-label-link" type="condition" conceptid="4087298" conceptname="Theft">theft</span> or misuse.</p>
<p>Life-threatening <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></p>
<p>Discuss the risk of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> with patients, explaining that the risk is greatest when starting NUCYNTA<span class="Sup">®</span> or when the dose is increased. Advise patients how to recognize <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and to seek medical attention if they are experiencing breathing difficulties.</p>
<p>Accidental Exposure</p>
<p>Instruct patients to take steps to store NUCYNTA<span class="Sup">®</span> securely. Accidental exposure, especially in children, may results in serious harm or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Advise patients to dispose of unused NUCYNTA<span class="Sup">®</span> by <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> the oral solution down the toilet.</p>
<p>Important Administration Instructions</p>
<p>Instruct patients how to properly take NUCYNTA<span class="Sup">®</span> oral solution, including the following:</p>
<ul>
<li>Advise patients to always use the enclosed calibrated oral syringe when administering NUCYNTA<span class="Sup">®</span> oral solution to ensure the dose is measured and administered accurately.</li>
<li>Using NUCYNTA<span class="Sup">®</span> oral solution exactly as prescribed to reduce the risk of life-threatening adverse reactions (e.g., <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>).</li>
<li>Not discontinuing NUCYNTA<span class="Sup">®</span> without first discussing the need for a tapering regimen with the prescriber.</li>
</ul>
<p>Risks from Concomitant Use of Alcohol and other CNS Depressants</p>
<p>Inform patients that the concomitant use of alcohol with NUCYNTA<span class="Sup">®</span> can increase the risk of life-threatening <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Instruct patients not to consume alcoholic beverages, as well as prescription and over-the-counter drug products that contain alcohol, during treatment with NUCYNTA<span class="Sup">®</span>.</p>
<p>Inform patients that potentially serious additive effects may occur if NUCYNTA<span class="Sup">®</span> is used with other CNS depressants, and not to use such drugs unless supervised by a health care provider.</p>
<p>Concurrent use of MAOI</p>
<p>Inform patients not to take NUCYNTA<span class="Sup">®</span> while using any drugs that inhibit monoamine oxidase. Patients should not start any new medications while taking NUCYNTA<span class="Sup">®</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></p>
<p>Inform patients that NUCYNTA<span class="Sup">®</span> could cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> if they are at risk for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or have <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. Patients should be advised to stop taking NUCYNTA<span class="Sup">®</span> if they have a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> while taking NUCYNTA<span class="Sup">®</span> and call their healthcare provider right away.</p>
<p><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></p>
<p>Inform patients that NUCYNTA<span class="Sup">®</span> could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs (including Serotonin Reuptake Inhibitors, Serotonin and Norepinephrine Reuptake Inhibitors and tricyclic antidepressants. Warn patients of the symptoms of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> and to seek medical attention right away if symptoms develop. </p>
<p>Instruct patients to inform their physicians if they are taking, or plan to take additional medications including CNS Depressants, MAO inhibitors, mixed agonists/antagonist opioid analgesics, anticholinergics, SSRIs, SNRIs, or tricyclic antidepressants.</p>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p>
<p>Inform patients that NUCYNTA<span class="Sup">®</span> may cause <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>. Instruct patients how to recognize symptoms of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span> and how to reduce the risk of serious consequences should <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occur (e.g., sit or lie down, carefully rise from a sitting or lying position).</p>
<p>Driving or Operating Heavy Machinery</p>
<p>Inform patients that NUCYNTA<span class="Sup">®</span> may impair the ability to perform potentially hazardous activities such as driving a car or operating heavy machinery. Advise patients not to perform such tasks until they know how they will react to the medication.</p>
<p><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p>
<p>Advise patients of the potential for severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, including management instructions and when to seek medical attention.</p>
<p><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></p>
<p>Inform patients that <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> has been reported with ingredients contained in NUCYNTA<span class="Sup">®</span>. Advise patients how to recognize such a reaction and when to seek medical attention.</p>
<p>Pregnancy</p>
<p>Advise female patients that NUCYNTA<span class="Sup">®</span> can cause fetal harm and to inform the prescriber if they are pregnant or plan to become pregnant. </p>
<p>Manufactured by:<br>Patheon Pharmaceuticals, Inc.<br>Cincinnati, OH  45237</p>
<p>Manufactured for:<br><br>Janssen Pharmaceuticals, Inc.<br>Titusville, NJ 08560 </p>
<p>Revised: November 2014<br><span class="Sup">©</span> Janssen Pharmaceuticals, Inc. 2009</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="MEDGUIDE"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Medication Guide<br>NUCYNTA<span class="Sup">®</span> (new-SINN-tah)<br>(tapentadol) oral solution, CII</span></p>
<p><span class="Bold">What is the most important information I should know about NUCYNTA<span class="Sup">®</span> oral solution</span>?</p>
<ul>
<li>Get emergency help right away if you take too much NUCYNTA<span class="Sup">®</span> oral solution (<span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>). NUCYNTA<span class="Sup">®</span> oral solution can cause life threatening breathing problems that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</li>
<li>Never give anyone else your NUCYNTA<span class="Sup">®</span> oral solution. They could die from taking it. Store NUCYNTA<span class="Sup">®</span> oral solution away from children and in a safe place to prevent <span class="product-label-link" type="condition" conceptid="4087298" conceptname="Theft">stealing</span> or abuse.  Selling or giving away NUCYNTA<span class="Sup">®</span> oral solution is against the law.</li>
<li>Do not change your dose. Take NUCYNTA<span class="Sup">®</span> oral solution exactly as prescribed by your healthcare provider.</li>
<li>Always use the oral syringe provided with NUCYNTA<span class="Sup">®</span> oral solution, 20 mg/mL to help make sure you measure the right amount.</li>
</ul>
<p><span class="Bold">What is NUCYNTA<span class="Sup">®</span> oral solution?</span></p>
<p>NUCYNTA<span class="Sup">®</span> oral solution is a strong prescription <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicine that contains an opioid (narcotic) that is used to treat moderate to severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> that is expected to last a short time. </p>
<p><span class="Bold">Who should not take NUCYNTA<span class="Sup">®</span> oral solution</span>?</p>
<p><span class="Bold">Do not take NUCYNTA<span class="Sup">®</span> oral solution if you:</span></p>
<ul>
<li>have severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, trouble breathing, or other lung problems</li>
<li>have a bowel blockage or narrowing of the stomach or intestines</li>
<li>take a monoamine oxidase inhibitor (MAOI) medicine or have taken an MAOI medicine within the last 14 days</li>
<li>are allergic to tapentadol or any of its ingredients.</li>
</ul>
<p><span class="Bold">What should I tell my healthcare provider before taking NUCYNTA<span class="Sup">®</span> oral solution?</span></p>
<p><span class="Bold">Before taking NUCYNTA<span class="Sup">®</span> oral solution,</span> tell your healthcare provider if you have a history of: 							</p>
<table class="Noautorules" width="60%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr>
<td align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></li>
<li>problems urinating</li>
</ul></td>
<td align="left"><ul>
<li>liver, kidney, thyroid problems</li>
<li>pancreas or gallbladder problems</li>
</ul></td>
</tr>
<tr><td align="left" colspan="2"><ul class="Disc"><li>abuse of street or prescription drugs, <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcohol addiction</span>, or mental health problems.</li></ul></td></tr>
</tbody>
</table>
<p><span class="Bold">Tell your healthcare provider if you are:</span></p>
<ul>
<li>
<span class="Bold">pregnant or planning to become pregnant. </span>NUCYNTA<span class="Sup">®</span> oral solution may harm your unborn baby.</li>
<li>
<span class="Bold">breastfeeding. </span>NUCYNTA<span class="Sup">®</span> oral solution may pass into your breast milk and harm your baby.</li>
<li>planning to have surgery</li>
<li>taking prescription or over-the-counter medicines, vitamins, or herbal supplements.</li>
</ul>
<p><span class="Bold">How should I take NUCYNTA<span class="Sup">®</span> oral solution?</span></p>
<ul>
<li>Do not change your dose. Take NUCYNTA<span class="Sup">®</span> oral solution exactly as prescribed by your healthcare provider.</li>
<li>If you miss a dose of NUCYNTA<span class="Sup">®</span> oral solution you can take the dose when you remember if you have <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, or you can wait for the next dose.</li>
<li>You can take NUCYNTA<span class="Sup">®</span> oral solution with or without food.</li>
<li>
<span class="Bold">Make sure you understand exactly how to measure your dose. </span>Always use the oral syringe provided with your NUCYNTA<span class="Sup">®</span> oral solution to help make sure you measure the right amount. Call your pharmacist if you have difficulties with measuring your medicine.</li>
<li><span class="Bold">Call your healthcare provider if the dose you are taking does not control your <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</span></li>
<li><span class="Bold">Do not stop taking NUCYNTA<span class="Sup">®</span> oral solution without talking to your healthcare provider.</span></li>
<li>After you stop taking NUCYNTA<span class="Sup">®</span> oral solution, flush any unused oral solution down the toilet.</li>
</ul>
<p><span class="Bold">What should I avoid while taking NUCYNTA<span class="Sup">®</span> oral solution?</span></p>
<p>While taking NUCYNTA<span class="Sup">®</span> oral solution <span class="Bold">do not</span>:</p>
<ul>
<li>Drive or operate heavy machinery, until you know how NUCYNTA<span class="Sup">®</span>   oral solution affects you. NUCYNTA<span class="Sup">®</span> oral solution can make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span>, dizzy, or lightheaded.</li>
<li>Drink alcohol or use prescription or over-the-counter medicines that contain alcohol.</li>
</ul>
<p><span class="Bold">What are the possible side effects of NUCYNTA<span class="Sup">®</span> oral solution?</span></p>
<p><span class="Bold">The possible side effects of NUCYNTA</span><span class="Sup">®</span><span class="Bold"> oral solution are:</span></p>
<ul><li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>. Call your healthcare provider if you have any of these symptoms and they are severe.</li></ul>
<p><span class="Bold">Get emergency medical help if you:</span></p>
<ul>
<li>have trouble breathing, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, fast heartbeat, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, tongue or throat, extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, or you are feeling <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>.</li>
<li>are feeling <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> or <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span>, have <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, pass out (become <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconscious</span>), feel overheated, have heavy <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> that is not due to activity, or loss of coordination.</li>
</ul>
<p>These are not all the possible side effects of NUCYNTA<span class="Sup">®</span> oral solution.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">For more information, go to dailymed.nlm.nih.gov</span></p>
<p>Manufactured by:Patheon Pharmaceuticals, Inc., Cincinnati, OH  45237</p>
<p>Manufactured for:Janssen Pharmaceuticals, Inc.,Titusville, NJ 08560</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Issue: November 2014</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="INSTRUCT"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">Instructions for Use</span></p>
<p><span class="Bold">NUCYNTA<span class="Sup">®</span> (tapentadol), CII</span></p>
<p><span class="Bold">oral solution</span></p>
<p><span class="Bold">20 mg/mL</span></p>
<p>Read the Instructions for Use before you start taking NUCYNTA<span class="Sup">®</span> oral solution and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.</p>
<p><span class="Bold">Important information about measuring NUCYNTA<span class="Sup">®</span> oral solution</span></p>
<ul>
<li><span class="Bold">Always use the oral syringe provided with your NUCYNTA<span class="Sup">®</span> oral solution to make sure you measure the right amount.</span></li>
<li>You will be provided (See <a href="#figA">Figure A</a>.): 									<ul class="Disc Solid">
<li>1 bottle of NUCYNTA<span class="Sup">®</span> oral solution</li>
<li>1 oral syringe</li>
<li>1 adapter</li>
</ul>
</li>
</ul>
<p><span class="Bold">If you do not receive an oral syringe with your NUCYNTA</span><span class="Sup">®</span><span class="Bold"> oral solution, ask your pharmacist to give you one.</span></p>
<p><a name="figA"></a><img alt="Figure A" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e921054f-b3f1-4624-8edd-f6628c6f0fd9&amp;name=nucynta-04.jpg"></p>
<p><span class="Bold">Before you use NUCYNTA</span><span class="Sup">®</span><span class="Bold"> oral solution for the first time:</span></p>
<table class="Noautorules" width="85%">
<col align="left" valign="top" width="5%">
<col align="left" valign="top" width="55%">
<col align="center" valign="top" width="40%">
<tbody class="Headless">
<tr>
<td align="left">1.</td>
<td align="left">Remove the child-resistant cap and completely remove the foil seal (See <a href="#figB">Figure B</a>).</td>
<td align="right">
<a name="figB"></a><img alt="Figure B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e921054f-b3f1-4624-8edd-f6628c6f0fd9&amp;name=nucynta-05.jpg">
</td>
</tr>
<tr>
<td align="left">2.</td>
<td align="left">Push the ribbed end of the adapter into the neck of the bottle until it is firmly in place. The bottom edge of the adapter should fully contact the top rim of the bottle (See <a href="#figC">Figure C</a>). Do not remove the adapter from the bottle after it is inserted.</td>
<td align="center">
<a name="figC"></a><img alt="Figure C" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e921054f-b3f1-4624-8edd-f6628c6f0fd9&amp;name=nucynta-06.jpg">
</td>
</tr>
<tr>
<td align="left" colspan="2">
<span class="Bold">To prepare a dose of NUCYNTA</span><span class="Sup">®</span><span class="Bold"> oral solution:</span>
</td>
<td align="center"></td>
</tr>
<tr>
<td align="left">3.</td>
<td align="left">Hold the oral syringe in one hand. With your other hand, fully push down (depress) the plunger (See <a href="#figD">Figure D</a>).</td>
<td align="center">
<a name="figD"></a><img alt="Figure D" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e921054f-b3f1-4624-8edd-f6628c6f0fd9&amp;name=nucynta-07.jpg">
</td>
</tr>
<tr>
<td align="left">4.</td>
<td align="left">Insert the tip of the oral syringe into the adapter (See <a href="#figE">Figure E</a>).</td>
<td align="center">
<a name="figE"></a><img alt="Figure E" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e921054f-b3f1-4624-8edd-f6628c6f0fd9&amp;name=nucynta-08.jpg">
</td>
</tr>
<tr>
<td align="left">5.</td>
<td align="left">Turn the bottle upside down. Pull back slowly on the oral syringe plunger to withdraw the dose prescribed by your healthcare provider (2.5 mL, 3.75 mL, or 5 mL). If you see air bubbles in the oral syringe, fully push in the plunger so that the oral solution flows back into the bottle. Then, withdraw your prescribed dose of oral solution (See <a href="#figF">Figure F</a>).</td>
<td align="center">
<a name="figF"></a><img alt="Figure F" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e921054f-b3f1-4624-8edd-f6628c6f0fd9&amp;name=nucynta-09.jpg">
</td>
</tr>
<tr>
<td align="left">6.</td>
<td align="left">Leave the oral syringe in the bottle adapter and turn the bottle right-side up. Place the bottle onto a flat surface. Remove the oral syringe from the bottle (See <a href="#figG">Figure G</a>).</td>
<td align="center">
<a name="figG"></a><img alt="Figure G" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e921054f-b3f1-4624-8edd-f6628c6f0fd9&amp;name=nucynta-10.jpg">
</td>
</tr>
<tr>
<td align="left">7.</td>
<td align="left">Place the tip of the oral syringe in your mouth. Squirt the oral solution into your mouth by pushing on the plunger until the oral syringe is empty (See <a href="#figH">Figure H</a>). </td>
<td align="center">
<a name="figH"></a><img alt="Figure H" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e921054f-b3f1-4624-8edd-f6628c6f0fd9&amp;name=nucynta-11.jpg">
</td>
</tr>
<tr>
<td align="left">8.</td>
<td align="left">Leave the adapter in the bottle. Put the child-resistant cap back on the bottle (See <a href="#figI">Figure I</a>). </td>
<td align="center">
<a name="figI"></a><img alt="Figure I" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e921054f-b3f1-4624-8edd-f6628c6f0fd9&amp;name=nucynta-12.jpg">
</td>
</tr>
<tr>
<td align="left">9.</td>
<td align="left">Remove the plunger from the oral syringe barrel. Rinse the oral syringe with water after each use and let it air dry.  When the oral syringe is dry, put the plunger back into the oral syringe barrel for the next use.  Do not throw away the oral syringe.<br><br>
</td>
<td align="center"></td>
</tr>
<tr>
<td align="left"></td>
<td align="left" colspan="2"><ul><li>Talk to your pharmacist if you have questions about how to use the oral syringe, or if you lose or misplace the oral syringe. </li></ul></td>
</tr>
</tbody>
</table>
<p><span class="Bold">What are the ingredients in NUCYNTA<span class="Sup">®</span> oral solution?</span></p>
<p>Active ingredient: tapentadol</p>
<p>Inactive ingredients: citric acid monohydrate, sucralose, raspberry flavor, sodium hydroxide, and purified water.</p>
<p><span class="Bold">How should I store NUCYNTA<span class="Sup">®</span> oral solution?</span></p>
<ul>
<li>Store NUCYNTA<span class="Sup">®</span> oral solution at room temperature between 68°F to 77°F (20°C to 25°C). </li>
<li>Store the NUCYNTA<span class="Sup">®</span> oral solution bottle upright after opening. Keep the oral syringe with your medicine.</li>
<li>After you stop taking NUCYNTA<span class="Sup">®</span> oral solution, flush the unused oral solution down the toilet.</li>
</ul>
<p><span class="Bold">Keep NUCYNTA<span class="Sup">®</span> oral solution out of the reach of children. </span></p>
<p>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured by:<br>Patheon Pharmaceuticals, Inc.<br>Cincinnati, OH  45237</p>
<p>Manufactured for:<br>Janssen Pharmaceuticals, Inc.<br>Titusville, NJ 08560</p>
<p>Revised: November 2014</p>
<p><span class="Sup">©</span> Janssen Pharmaceuticals, Inc. 2009</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 100 mL Bottle Label</h1>
<p class="First"><span class="Bold">NDC 50458-817-01<br>100mL</span></p>
<p><span class="Bold">Nucynta</span><span class="Sup">®</span><br>(tapentadol)<br>Oral Solution</p>
<p><span class="Bold">20mg/mL<br>CII</span></p>
<p>Each 1mL contains 20mg of <br>tapentadol in solution</p>
<p><span class="Bold">ATTENTION PHARMACIST: Dispense <br>the accompanying Medication<br>Guide to each patient<br><br></span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 100 mL Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e921054f-b3f1-4624-8edd-f6628c6f0fd9&amp;name=nucynta-13.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NUCYNTA 		
					</strong><br><span class="contentTableReg">tapentadol hydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50458-817</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>tapentadol hydrochloride</strong> (tapentadol) </td>
<td class="formItem">tapentadol</td>
<td class="formItem">20 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>citric acid monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sucralose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">RASPBERRY</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50458-817-01</td>
<td class="formItem">100 mL in 1 BOTTLE; Combination Product Type = C102834</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:50458-817-02</td>
<td class="formItem">200 mL in 1 BOTTLE; Combination Product Type = C102834</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203794</td>
<td class="formItem">10/15/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Janssen Pharmaceuticals, Inc.
							(063137772)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Patheon Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">005286822</td>
<td class="formItem">MANUFACTURE(50458-817), ANALYSIS(50458-817)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Noramco, Inc.</td>
<td class="formItem"></td>
<td class="formItem">057234486</td>
<td class="formItem">API MANUFACTURE(50458-817)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d3931d30-492b-4404-89ed-69c02160d8d0</div>
<div>Set id: e921054f-b3f1-4624-8edd-f6628c6f0fd9</div>
<div>Version: 4</div>
<div>Effective Time: 20141125</div>
</div>
</div> <div class="DistributorName">Janssen Pharmaceuticals, Inc.</div></p>
</body></html>
